TrialClinical pharmacokinetics2025

Pharmacokinetics, Pharmacodynamics, and Safety of Olorigliflozin in Individuals with Type 2 Diabetes Mellitus with or without Renal Impairment: A Single-Center, Single-Dose, Open-Label Trial.

Man Chen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.